Raphael Pharmaceutical Inc.
RAPH · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $776 | $569 | $1,178 | $776 |
| G&A Expenses | $733 | $763 | $2,139 | $853 |
| SG&A Expenses | $733 | $763 | $2,139 | $853 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $1,509 | $1,332 | $3,317 | $1,629 |
| Operating Income | -$1,509 | -$1,332 | -$3,317 | -$1,629 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$10 | -$12 | -$41 | $5 |
| Pre-Tax Income | -$1,519 | -$1,344 | -$3,358 | -$1,624 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1,519 | -$1,344 | -$3,358 | -$1,624 |
| % Margin | – | – | – | – |
| EPS | -0.081 | -0.08 | -0.23 | -0.1 |
| % Growth | -1.1% | 65% | -130% | – |
| EPS Diluted | -0.081 | -0.08 | -0.23 | -0.1 |
| Weighted Avg Shares Out | 18,674 | 16,717 | 14,342 | 15,484 |
| Weighted Avg Shares Out Dil | 18,674 | 16,717 | 14,342 | 15,484 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $5 |
| Interest Expense | $2 | $3 | $3 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$1,509 | -$1,332 | -$3,317 | -$1,629 |
| % Margin | – | – | – | – |